Eli Lilly has reached a deal to integrate DexCom’s continuous glucose monitoring (CGM) into its personalised diabetes management system.

Lilly’s diabetes system is currently in development and incorporates connected insulin delivery devices, software and analysis techniques.

As part of the non-exclusive agreement, Dexcom’s CGM devices will integrate into Lilly’s pen-based and pump-based insulin delivery devices.

DexCom’s CGM systems include app-based remote monitoring and alarm functions.

Lilly Diabetes Connected Care and Insulins senior vice president Mike Mason said: “We’re excited to include Dexcom’s technology in the solutions we deliver to people with diabetes to help improve health outcomes by delivering actionable insights in one connected system.

“As we integrate our expertise and insights with those from our partners, like Dexcom, we are aiming to not only transform the way we develop and deliver medicine but to transform how people manage their diabetes.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Through the partnership with Dexcom, Lilly’s intends to offer type 1 and type 2 diabetes patients with personalised information and guidance and simplify management of their diabetes.

Globally, approximately 425 million adults are suffering from diabetes, with Type 2 being the most common form.

The pen-based platform is designed to integrate personalised data from a pre-filled, disposable insulin pen, with data from glucose-sensing technology into a compatible software application.

The pump-based platform, a hybrid closed-loop system, is designed to automate insulin dosing through the integration of an insulin pump, continuous glucose monitor and handheld controller or smartphone application.

Dexcom chief commercial officer Rick Doubleday said: “CGMs provide people with diabetes and their healthcare team with important real-time data that can help alleviate the burden of diabetes management, including overall glucose level trends and information on time spent in target blood glucose range.

“We’re looking forward to expanding our collaboration with Lilly as we integrate our technology into their system and believe it will help reduce some of the complexity that can come from managing diabetes every day.”